scholarly journals Combined Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation in Mucopolysacharidosis Type VI

2011 ◽  
pp. 103-106 ◽  
Author(s):  
D Sillence ◽  
K Waters ◽  
S Donaldson ◽  
P J Shaw ◽  
C Ellaway
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Hematopoietic Stem ◽  
Enzyme Replacement

scholarly journals Enzyme Replacement Therapy and Hematopoietic Stem Cell Transplantation Results in Patients with Hurler Syndrome: Clinical Cases

2019 ◽  
Vol 18 (3) ◽  
pp. 196-202
Author(s):  
Nato D. Vashakmadze ◽  
Leyla S. Namazova-Baranova ◽  
Natalia V. Zhurkova ◽  
Ekaterina Yu. Zakharova ◽  
Svetlana V. Mikhaylova ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Cell Transplantation ◽  
Hurler Syndrome ◽  
Hematopoietic Stem ◽  
Enzyme Replacement ◽  
Mps I

Mucopolysaccharidosis type I (MPS I) is the hereditary disease characterized with alpha-L-iduronidase activity decrease and further accumulation of heparan and dermatan sulfate in lysosomes. MPS I is rare autosomal recessive disorder with incidence of 0.5–4 cases on 100.000 live-birth infants. Meantime there two approaches in MPS I treatment: hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT). HSCT can be the best option for treatment of patients with severe MPS I (Hurler syndrome). Successful engraftment moderates such clinical signs as obstructive airway diseases, hepatosplenomegaly, cardiovascular system dysfunctions. HSCT prevents cognitive functions decline and other pathologic features of central nervous system. Presented clinical cases show various clinical courses according to age of diagnosis, ERT onset and HSCT implementation.

Sign in / Sign up

Export Citation Format

Share Document